On December 9th, the "High-quality Development of Chinese Medicine Industry in China and the 4th China Chinese Medicine Brand Building Conference" hosted by China Association of Traditional Chinese Medicine was held in Beijing. Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited was selected as the 17th in the TOP100 list of proprietary Chinese medicine industry in 2023, and ranked 10th in the selection of innovative TCM brand enterprises in 2023. 

Leaders from the National Development and Reform Commission, the National Health Commission, the National Medical Products Administration, National Administration of traditional Chinese Medicine and other ministries, as well as many academicians, experts and entrepreneurs, totalling more than 800 persons, attended the conference. With the theme of "Brand-oriented, Inheritance and Innovation, and Promoting the High-quality Development of TCM Industry", the conference set up a main forum and various sub-forums such as TCM agriculture, TCM innovation, homology of medicine and food, TCM industry and new retail of medicine. 

On December 10th, the conference released the TCM brand research report for the year 2023, and published the TOP100 list of proprietary Chinese medicine industry in 2023, which listed Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in the 17th order. 

 In 2023, China Association of Traditional Chinese Medicine launched the "Innovative Brand Enterprise of Traditional Chinese Medicine" for the first time, which selects enterprises from four dimensions, namely, evaluation index of new product vitality, evaluation index of technology improvement, evaluation index of product dissemination and evaluation index of science and technology reward. Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited was selected as an innovative brand enterprise of traditional Chinese medicine in 2023 and ranked 10th. 

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited is a enterprise group with complete chain in traditional Chinese medicine industry, which integrates medicinal materials planting and processing, pharmaceutical research and development, pharmaceutical production, pharmaceutical commerce and big health industry as a whole. With green Chinese medicine as the core and brand as the guide, the company focuses on 599 varieties, highlighting the "three cores and nine wings", focusing on three core areas, namely, cardiovascular and cerebrovascular diseases, skin wound repair, and high-quality traditional Chinese medicine for health care, making unremitting efforts to build the most valuable modern enterprise in green Chinese medicine in China and realize the goal of being the leader in innovative Chinese medicine field.